| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -860,414 | -628,621 | -62,913 | -160,112 |
| Non-cash interest expense | - | - | - | 0 |
| Amortization of discount on short-term investments | 3,989 | 3,989 | 2,966 | 4,926 |
| Unrealized foreign exchange (gain) loss | 414 | 463 | 224 | -400 |
| Reclassification of currency translation gain | - | - | - | 0 |
| Impairment of fixed assets | - | - | - | 0 |
| Depreciation | 104 | 62 | 25 | 67 |
| Gain on disposal of assets | - | - | - | 0 |
| Stock-based compensation | 620,641 | 489,880 | 11,096 | 39,966 |
| Acquired in-process research and development expense | - | - | - | 15,007 |
| Accounts receivable | - | - | - | 0 |
| Prepaid expenses | - | - | - | -572 |
| Other current and long-term assets | - | - | - | -2,105 |
| Acquired in-process research and development expense | 0 | 0 | - | - |
| Research and development tax credit receivable | - | - | - | -738 |
| Prepaid expenses and other current assets | -3,658 | 81 | -1,850 | - |
| Accounts payable | 17,448 | 18,287 | 356 | 486 |
| Accrued liabilities | 7,397 | 6,452 | 1,611 | 9,894 |
| Other current liabilities | 134 | -342 | -1,046 | - |
| Other non-current liabilities | 82 | 52 | 25 | 70 |
| Other long-term assets | 4,528 | 3,672 | 1,419 | - |
| Accrued compensation | -1,047 | -5,407 | -7,588 | 2,515 |
| Operating lease right-of-use assets and lease liabilities, net | -64 | -70 | 25 | 215 |
| Net cash used in operating activities | -220,992 | -127,912 | -61,168 | -93,433 |
| Purchases of property and equipment | 493 | 422 | 422 | 125 |
| Proceeds from sale of property and equipment | - | - | - | 0 |
| Purchase of short-term investments | 0 | 0 | 0 | 530,544 |
| Maturities and sales of short-term investments | 311,340 | 311,340 | 160,532 | 256,853 |
| Payments to akeso for upfront milestone payments and associated direct transaction costs | 0 | - | - | 15,007 |
| Net cash provided by (used in) investing activities | 310,847 | 310,918 | 160,110 | -288,823 |
| Proceeds from the issuance of common stock via private placements, net of offering costs | 0 | 0 | - | 434,961 |
| Proceeds from issuance of common stock-At Market Offering | 31,764 | - | - | 43,037 |
| Proceeds from the issuance of common stock-Rights Offering | - | - | - | 0 |
| Proceeds received related to the exercise of warrants | 7,315 | 7,315 | 5,658 | 101 |
| Repayment of related party promissory notes | 0 | - | - | 75,500 |
| Proceeds received related to employee stock awards and purchase plans | 4,633 | 2,584 | 2,019 | 2,240 |
| Net cash provided by financing activities | 43,712 | 9,899 | 7,677 | 404,839 |
| Effect of exchange rate changes on cash | 121 | 99 | 38 | 90 |
| Increase in cash, cash equivalents and restricted cash | 133,688 | 193,004 | 106,657 | 22,673 |
| Cash and cash equivalents at beginning of period | 105,187 | 105,187 | 105,187 | 71,425 |
| Cash and cash equivalents at end of period | 238,875 | 298,191 | 211,844 | 94,098 |
Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (SMMT)